Basilea raises 2026 guidance, lifts operating profit forecast to CHF 115 million

Basilea Pharmaceutica raised its 2026 financial outlook, now expecting an operating profit of CHF 115 million, up from prior guidance of CHF 70 million. Revenue from core anti-infective products Cresemba and Zevtera is now projected at CHF 250 million, up from CHF 210 million.

Detected & updated continuously · Source: Nebula